Guidance on the implementation and reporting of a drug safety Bayesian network meta‐analysis
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
The Drug Information Association Bayesian Scientific Working Group (BSWG) was formed in 2011 with a vision to ensure that Bayesian methods are well understood and broadly utilized for design and analysis and throughout the medical product development process, and to improve industrial, regulatory, and economic decision making. The group, composed of individuals from academia, industry, and regulatory, has as its mission to facilitate the appropriate use and contribute to the progress of Bayesian methodology. In this paper, the safety sub‐team of the BSWG explores the use of Bayesian methods when applied to drug safety meta‐analysis and network meta‐analysis. Guidance is presented on the conduct and reporting of such analyses. We also discuss different structural model assumptions and provide discussion on prior specification. The work is illustrated through a case study involving a network meta‐analysis related to the cardiovascular safety of non‐steroidal anti‐inflammatory drugs. Copyright © 2013 John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gelman, A. (2006) · Bayesian Analysis · doi:10.1214/06-ba117a · Cited by 4,050 · cited 1×
“as half-Cauchy (or half-normal) with an appropriate scale parameter has been recommended [40].”
BackgroundA Re-Evaluation of Random-Effects Meta-Analysis
Higgins, J. P. T., Thompson, S. G., & Spiegelhalter, D. J. (2009) · Journal of the Royal Statistical Society Series A: Statistics in Society · doi:10.1111/j.1467-985x.2008.00552.x · Cited by 2,569
Checking consistency in mixed treatment comparison meta-analysis
Dias, S., Welton, N. J., Caldwell, D. M., & Ades, A. E. (2010) · Statistics in Medicine · doi:10.1002/sim.3767 · Cited by 2,521 · cited 1×
“An alternative approach, described in [72], introduces node-splitting method, which enables a test of consistency through the posterior distribution of an additional parameter”
MethodCardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial
Bresalier, R. S., Sandler, R. S., Quan, H., Bolognese, J. A., Oxenius, B., Horgan, K., Lines, C., Riddell, R., Morton, D., Lanas, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050493 · Cited by 2,519 · cited 1×
“Concerns about the cardiovascular safety of NSAIDs arose since the withdrawal of rofecoxib [57], a selective COX-2 inhibitor, from the market in 2004 after the results of a randomized placebo-controlled trial showed an increased risk of cardiovascular events associated with the drug [58].”
BackgroundWhat to add to nothing? Use and avoidance of continuity corrections in meta‐analysis of sparse data
J. Sweeting, M., J. Sutton, A., & C. Lambert, P. (2004) · Statistics in Medicine · doi:10.1002/sim.1761 · Cited by 1,734
Uncertain Judgements: Eliciting Experts' Probabilities
O'Hagan, A., Buck, C. E., Daneshkhah, A., Eiser, J. R., Garthwaite, P. H., Jenkinson, D. J., Oakley, J. E., & Rakow, T. (2006) · doi:10.1002/0470033312 · Cited by 1,550
Network meta‐analysis for indirect treatment comparisons
Lumley, T. (2002) · Statistics in Medicine · doi:10.1002/sim.1201 · Cited by 1,206 · cited 21×
“Following the work on two-treatment meta-analysis in [11], an alternative way to parametrize NMA involves the use of a classical two-way linear predictor, with main effects for treatment and trial [37, 39].”
BackgroundMethodInfluentialEvaluation of networks of randomized trials
Salanti, G., Higgins, J. P., Ades, A., & Ioannidis, J. P. (2008) · Statistical Methods in Medical Research · doi:10.1177/0962280207080643 · Cited by 1,078
Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events
Bradburn, M. J., Deeks, J. J., Berlin, J. A., & Russell Localio, A. (2007) · Statistics in Medicine · doi:10.1002/sim.2528 · Cited by 938 · cited 1×
“However, in a meta-analysis involving rare binary events, it is acknowledged that continuity corrections can be very influential and their use can produce highly biased results and misleading conclusions [35, 36].”
BackgroundRisk of cardiovascular events and rofecoxib: cumulative meta-analysis
Jüni, P., Nartey, L., Reichenbach, S., Sterchi, R., Dieppe, P. A., & Egger, M. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17514-4 · Cited by 846
Cited by
Network meta-analysis: a technique to gather evidence from direct and indirect comparisons
Tonin, F. S., Rotta, I., Mendes, A. M., & Pontarolo, R. (2017) · Pharmacy Practice · doi:10.18549/pharmpract.2017.01.943 · Cited by 405
GetReal in network meta-analysis: a review of the methodology
Efthimiou, O., Debray, T. P. A., van Valkenhoef, G., Trelle, S., Panayidou, K., Moons, K. G. M., Reitsma, J. B., Shang, A., Salanti, G., & on behalf of GetReal Methods Review Group (2016) · Research Synthesis Methods · doi:10.1002/jrsm.1195 · Cited by 401
“Ohlssen et al. (2013) presented a checklist of items that should be reported in a drug safety Bayesian NMA while Ades et al. (2013) and Mills et al. (2012a) gave guidelines for those reviewing an NMA for the purposes of decision making.”
BackgroundMethodInfluentialHutton, B., Salanti, G., Chaimani, A., Caldwell, D. M., Schmid, C., Thorlund, K., Mills, E., Catalá-López, F., Turner, L., Altman, D. G., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0092508 · Cited by 105
Leng, M., Zhao, Y., & Wang, Z. (2020) · International Journal of Nursing Studies · doi:10.1016/j.ijnurstu.2019.103489 · Cited by 48
The Medical Outreach Team of the Drug Information Association Bayesian Scientific Working Group, Bray, R., Hartley, A., Wenkert, D., Muehlemann, N., Natanegara, F., Harrell, F. E., Wang, F., & Clark, J. (2023) · Therapeutic Innovation & Regulatory Science · doi:10.1007/s43441-022-00482-1 · Cited by 9
Metadata
- Authors
- Ohlssen, D., Price, K. L., Amy Xia, H., Hong, H., Kerman, J., Fu, H., Quartey, G., Heilmann, C. R., Ma, H., & Carlin, B. P.
- Venue
- Pharmaceutical Statistics
- Publisher
- Wiley
- Published
- 2013-08-30
- Volume
- 13
- Issue
- 1
- Pages
- 55-70
- ISSN
- 1539-1604 (ISSN-L)
- 1539-1612
- OpenAlex
- W2029967109
- Cited by
- 34
- References
- 17
- FWCI
- 3.73
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Guidance on the implementation and reporting of a drug safety Bayesian network meta‐analysis. https://app.cochat.ai/papers/10.1002/pst.1592
- The paper
- Ohlssen, D., Price, K. L., Amy Xia, H., Hong, H., Kerman, J., Fu, H., Quartey, G., Heilmann, C. R., Ma, H., & Carlin, B. P. (2014). Guidance on the implementation and reporting of a drug safety Bayesian network meta‐analysis. Pharmaceutical Statistics. https://doi.org/10.1002/pst.1592
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.